Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
ifabotuzumab (KB004)
i
Other names:
KB004 , KB-004
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Humanigen, Olivia Newton-John Cancer Research Institute
Drug class:
EPH receptor inhibitor, EphA3 inhibitor
Related drugs:
‹
E7050 (1)
E7050 (1)
›
Associations
(1)
News
Trials
Filter by
Latest
3years
A Trial of KB004 in Patients With Glioblastoma (clinicaltrials.gov)
P1, N=12, Completed, Olivia Newton-John Cancer Research Institute | Active, not recruiting --> Completed
3 years ago
Clinical • Trial completion
|
EPHA3 (EPH receptor A3)
|
ifabotuzumab (KB004)
over3years
A Trial of KB004 in Patients With Glioblastoma (clinicaltrials.gov)
P1, N=12, Active, not recruiting, Olivia Newton-John Cancer Research Institute | Trial completion date: Apr 2021 --> Sep 2021
over 3 years ago
Clinical • Trial completion date
|
EPHA3 (EPH receptor A3)
|
ifabotuzumab (KB004)
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login